Healthcare · Biotechnology
Price
$3.01
Market Cap
$200,586
Employees
49
Beta
-0.10
Avg Volume
88,735
CEO
Lisa A. Conte
Business Description
Jaguar Health, Inc., a commercial-stage pharmaceutical firm, specializes in developing prescription therapies for both human and animal patients afflicted by gastrointestinal ailments, particularly chronic and severe diarrhea. Its operations are structured into two distinct divisions: Human Health and Animal Health. Presently, the company markets Mytesi, an approved medication providing symptomatic relief for noninfectious diarrhea experienced by adults with HIV/AIDS undergoing antiretroviral therapy. Beyond its commercial product, Jaguar Health is actively advancing Crofelemer, the active pharmaceutical ingredient in Mytesi, for a broad spectrum of additional indications. These include managing diarrhea associated with cancer therapy, seeking orphan drug designation for symptomatic relief in infants and children with congenital diarrheal disorders, and for adult and pediatric patients suffering from short bowel syndrome with intestinal failure. Further potential applications encompass supportive care for diarrhea linked to inflammatory bowel diseases, diarrhea-predominant irritable bowel syndrome (IBS-D), and idiopathic or functional diarrhea. Their pipeline also features lechlemer, a next-generation anti-secretory agent being developed to combat cholera. In the animal health sector, they are developing Canalevia, an oral, plant-derived drug candidate designed to address chemotherapy-induced diarrhea and exercise-induced diarrhea in canines. Established in 2013, Jaguar Health, Inc. maintains its headquarters in San Francisco, California.
Business History
Price Overview
Last updated: Jun 27, 2026 11:25am (just now)$3.01
+0.28 (+10.26%)
Day Range
$2.71 – $3.05
52-Week Range
$2.12 – $97.65
50-Day MA
$5.07
200-Day MA
$32.58
Volume
115,632.00
Analyst Price Targets
Low
$3.21
Consensus
$3.21
High
$3.21
(2 analysts)
Share Structure
Outstanding
66,640.00
Float
55,020.00
Free Float
82.6%
High free float
— 82.6% of shares trade freely, ~17.4% held by insiders/institutions
Very liquid — most shares trade freely. Low insider ownership can mean less management alignment, but makes large position sizing straightforward.
Small absolute float (0.1M shares) — even with a decent free float %, volume can be thin. Check average daily volume before sizing a position.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
0.00
Stock Price: $3.01
EPS (Diluted): -803.95
EPS (Diluted): -803.95
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
-0.13
Stock Price: $3.01
Total Equity: -$17.29M
Shares: 66,640
Total Equity: -$17.29M
Shares: 66,640
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-0.97
Market Cap: $200,586
Total Debt: $42.52M
Cash: $968,000
EBITDA: -$37.89M
Total Debt: $42.52M
Cash: $968,000
EBITDA: -$37.89M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$44.8M
Market Cap: $200,586
Total Debt: $42.52M
Cash: $968,000
Total Debt: $42.52M
Cash: $968,000
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
0.19
Stock Price: $3.01
Revenue: $11.51M
Shares: 66,640
Revenue: $11.51M
Shares: 66,640
EV/Sales (Total value vs revenue — works when P/E can't)
API3.89
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
67.2%
Gross Profit: $7.74M
Revenue: $11.51M
Revenue: $11.51M
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
-398.8%
Operating Income: -$45.91M
Revenue: $11.51M
Revenue: $11.51M
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
-465.4%
Net Income: -$53.58M
Revenue: $11.51M
Revenue: $11.51M
ROE (Profit from shareholder equity)
APINet Income / Total Equity
764.5%
Net Income: -$53.58M
Total Equity: -$17.29M
Total Equity: -$17.29M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-89.3%
Operating Income: -$45.91M
Tax Rate: 0.8%
Equity: -$17.29M
Total Debt: $42.52M
Cash: $968,000
Tax Rate: 0.8%
Equity: -$17.29M
Total Debt: $42.52M
Cash: $968,000
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
0.50
Current Assets: $20.35M
Current Liabilities: $40.65M
Current Liabilities: $40.65M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
-2.46
Short-Term Debt: $27.44M
Long-Term Debt: $15.08M
Total Debt: $42.52M
Total Equity: -$17.29M
Long-Term Debt: $15.08M
Total Debt: $42.52M
Total Equity: -$17.29M
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$172.73
Revenue: $11.51M
Shares: 66,640
Shares: 66,640
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$-259.44
Total Equity: -$17.29M
Shares: 66,640
Shares: 66,640
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$86.63
Operating CF: $5.80M
CapEx: -$25,000
Shares: 66,640
CapEx: -$25,000
Shares: 66,640
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $3.01
Stock Price: $3.01
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$53.58M
Net Income: -$53.58M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares JAGX against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 26, 2026 9:07am (1d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $4.3M | $12.0M | $9.8M | $11.7M | $11.5M |
| Cost of Revenue | $2.3M | $2.0M | $2.0M | $2.0M | $3.8M |
| Gross Profit | $2.0M | $9.9M | $7.7M | $9.7M | $7.7M |
| Operating Expenses | $42.7M | $44.4M | $42.0M | $40.6M | $53.6M |
| Operating Income | -$40.7M | -$34.4M | -$34.3M | -$30.8M | -$45.9M |
| Net Income | -$52.6M | -$47.5M | -$41.3M | -$38.5M | -$53.6M |
| EBITDA | -$42.4M | -$33.4M | -$32.8M | -$36.7M | -$37.9M |
| EPS | $-4,631,759.00 | $-1,899,528.00 | $-93,992.00 | $-4,574.07 | $-803.95 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 26, 2026 9:07am (1d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $17.1M | $5.5M | $6.5M | $8.0M | $968,000 |
| Total Current Assets | $28.4M | $22.3M | $28.0M | $32.2M | $20.3M |
| Total Assets | $53.3M | $47.5M | $50.8M | $53.4M | $38.3M |
| Current Liabilities | $15.5M | $30.3M | $14.0M | $19.7M | $40.7M |
| Long-Term Debt | $25.0M | $17.7M | $31.0M | $23.5M | $15.1M |
| Total Liabilities | $41.4M | $48.8M | $45.9M | $46.9M | $57.0M |
| Total Equity | $11.6M | $-657,000 | $5.0M | $7.3M | -$17.3M |
| Retained Earnings | -$219.5M | -$266.9M | -$308.2M | -$346.5M | -$399.9M |
Cash Flow (Annual)
Last updated: Jun 26, 2026 9:07am (1d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$35.0M | -$33.1M | -$33.2M | -$29.4M | $5.8M |
| Capital Expenditure | $-6,000 | -$1.7M | $0 | $-231,000 | $-25,000 |
| Free Cash Flow | -$35.0M | -$34.8M | -$33.2M | -$29.6M | $5.8M |
| Acquisitions (net) | $247,000 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | -$31.1M |
| Net Change in Cash | $9.0M | -$11.6M | $1.0M | $1.5M | -$38.4M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 11:25am (just now)| Metric | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| Revenue |
$11.3M $11.3M – $11.3M
|
$12.6M $12.6M – $12.6M
|
$2.5M $2.5M – $2.5M
|
$4.1M $4.1M – $4.1M
|
| EBITDA |
-$11.3M -$11.3M – -$11.3M
|
-$12.6M -$12.6M – -$12.6M
|
-$2.5M -$2.5M – -$2.5M
|
-$4.1M -$4.1M – -$4.1M
|
| Net Income |
-$46.6M -$46.6M – -$46.6M
|
-$29.0M -$29.0M – -$29.0M
|
$-279,892 $-279,892 – $-279,892
|
$-629,757 $-629,757 – $-629,757
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 26, 2026 9:07am (1d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +175.8% | -18.4% | +19.8% | -1.5% |
| Gross Profit Growth | +396.4% | -22.3% | +26.0% | -20.5% |
| Operating Income Growth | +15.5% | +0.4% | +10.1% | -48.9% |
| Net Income Growth | +9.8% | +13.0% | +6.8% | -39.2% |
| EBITDA Growth | +21.2% | +1.9% | -11.9% | -3.4% |
Insider Trading (Recent)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2025-12-11 | MICEK JOHN | A-Award | 7,377.00 | $0.00 | $0 |
| 2025-12-11 | MICEK JOHN | A-Award | 7,377.00 | $1.44 | $10,623 |
| 2025-12-11 | King Steven R. | A-Award | 11,740.00 | $0.00 | $0 |
| 2025-12-11 | King Steven R. | A-Award | 11,740.00 | $1.44 | $16,906 |
| 2025-12-11 | CONTE LISA A | A-Award | 28,592.00 | $0.00 | $0 |
| 2025-12-11 | CONTE LISA A | A-Award | 28,592.00 | $1.44 | $41,172 |
| 2025-12-11 | Wolin Jonathan S. | A-Award | 11,740.00 | $0.00 | $0 |
| 2025-12-11 | Wolin Jonathan S. | A-Award | 11,740.00 | $1.44 | $16,906 |
| 2025-12-11 | Chaturvedi Pravin R | A-Award | 11,740.00 | $0.00 | $0 |
| 2025-12-11 | Chaturvedi Pravin R | A-Award | 11,740.00 | $1.44 | $16,906 |
| 2025-12-11 | BOCHNOWSKI JAMES J | A-Award | 6,363.00 | $0.00 | $0 |
| 2025-12-11 | BOCHNOWSKI JAMES J | A-Award | 6,363.00 | $1.44 | $9,163 |
| 2025-12-11 | Siegel Jonathan B. | A-Award | 7,377.00 | $0.00 | $0 |
| 2025-12-11 | Siegel Jonathan B. | A-Award | 7,377.00 | $1.44 | $10,623 |
| 2025-12-11 | Jayasuriya Anula | A-Award | 5,870.00 | $0.00 | $0 |
| 2025-12-11 | Jayasuriya Anula | A-Award | 5,870.00 | $1.44 | $8,453 |
| 2025-12-11 | Lizak Carol R. | A-Award | 11,740.00 | $0.00 | $0 |
| 2025-12-11 | Lizak Carol R. | A-Award | 11,740.00 | $1.44 | $16,906 |
| 2025-08-28 | Lincoln Alternative Strategies LLC | 0.00 | $0.00 | $0 | |
| 2025-06-24 | Siegel Jonathan B. | A-Award | 9,462.00 | $5.56 | $52,561 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for JAGX — it's generated by the pipeline (
market-narrative step).
No community reviews yet for JAGX.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30